Discussion on the biologic therapy of inflammatory bowel disease.
Merger
M
M
Herfarth
H
H
Scholmerich
J
J
Andus
T
T
Färber
L
L
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D001691:Biological Therapy / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab